[Mesenchymal stem cell treatment in autoimmune diseases]

Area of Science:

• Immunology
• Regenerative Medicine
• Rheumatology

Background:

• Mesenchymal stromal cells (MSC) exhibit potent immunomodulatory and tissue repair capabilities.
• Impaired MSC function has been observed in vitro in rheumatic diseases, but its in vivo relevance remains unclear.
• MSC transplantation (MSCT) is being explored as a therapeutic strategy for autoimmune rheumatic conditions.

Purpose of the Study:

• To evaluate the potential of MSC and MSCT in treating autoimmune rheumatic diseases.
• To review existing clinical trial data on MSCT for these conditions.
• To identify unanswered questions regarding MSC therapy for rheumatic disorders.

Main Methods:

• Review of experimental data on MSC function in rheumatic diseases.
• Analysis of preliminary clinical trial outcomes for MSCT in systemic lupus erythematosus, systemic sclerosis, and Sjogren's syndrome.
• Identification of key areas requiring further investigation.

Main Results:

• MSC possess significant immunomodulatory and differentiation potential relevant to tissue repair.
• Initial clinical trials suggest positive therapeutic effects of MSCT in specific autoimmune rheumatic diseases.
• Evidence for impaired MSC function in vitro in rheumatic diseases exists, but clinical significance is not yet established.

Conclusions:

• Allogeneic and autologous MSCT represent a promising therapeutic avenue for autoimmune rheumatic diseases.
• Further research is crucial to address long-term benefits, safety, optimal MSC sourcing, cultivation, and administration.
• Unanswered questions necessitate rigorous investigation before widespread clinical adoption.